G1 Therapeutics Fails Late-Stage Breast Cancer Trial, Plans ‘Targeted’ Headcount Reductions

G1 Therapeutics announced Monday that its drug Cosela (trilaciclib) in a Phase III trial failed to show a statistically significant treatment effect in triple-negative breast cancer patients, as the company takes measures to reach profitability in the second half of 2025.